The Observational and Medical Outcomes Partnerships (OMOP) common data model (CDM) provides a framework for standardising observational health data. Multi-database studies can then be performed without a need to pool patient-level data across network sites, and with only aggregate results shared.
In this project we are mapping data from biologic registries to the OMOP CDM. This will then allow for an assessment of comorbidity in people with severe RA in Europe, and provide the basis for further collaborative projects.
Biologic/rheumatology registries from 5 countries were mapped to the OMOP Common Data Model. Such data is the beginning to enable future multinational federated collaborations (i.e. with no transfer of patient-level data). We run quality control checks, including conformity, plausibility, and completeness. The resulting data are available for future collaboration and distributed network analyses beyond our work/research.
Second, we created an analytical package to assess the presence of comorbidities at each of the registries. Enabled by the use of the same CDM, the same analytical code run across sites, with only aggregated results shared between partners. Two key learnings are: 1) there is great heterogeneity in the recording of comorbidities in biologic registries across Europe; and 2) comorbidities are very common amongst patients with RA included in biologic registries. More work needs to be done to harmonise the information on comorbidity contained in European biologic registries.
We speculated that by curating data to a common data model, we would be able to analyse the presence of comorbidities (concomitant conditions) amongst people with Rheumatoid Arthritis registered in existing biologic registries across Europe. We processed data accordingly in collaboration with colleagues from Czechia, Germany, Spain, Switzerland, and the UK.
After doing so, we looked at comorbidities, and learned that such information is recorded in very different ways in the different databases. More work is therefore needed to harmonise biologic registries data to enable future collaboration on the association between comorbidity and patient-relevant outcomes.